LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Akcijų sąrašas・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

17.15 -0.17

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

16.74

Max

17.24

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-607K -51M
Pardavimai	-28M 100M
Pelnas, tenkantis vienai akcijai	-0.46
Pelno marža	-51.215
Darbuotojai	1,784
EBITDA	4.1M -44M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+89.58% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-541M 1.8B
Ankstesnė atidarymo kaina	17.32
Ankstesnė uždarymo kaina	17.15

Naujienos nuotaikos

By Acuity

34%

66%

91 / 344 reitingas Healthcare

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-02 20:30; UTC

Uždarbis

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2026-06-02 23:58; UTC

Rinkos pokalbiai

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2026-06-02 23:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-02 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2026-06-02 23:41; UTC

Rinkos pokalbiai

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2026-06-02 23:01; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2026-06-02 23:01; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2026-06-02 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2026-06-02 22:57; UTC

Rinkos pokalbiai

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2026-06-02 22:50; UTC

Rinkos pokalbiai

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2026-06-02 21:07; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-02 21:07; UTC

Rinkos pokalbiai

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2026-06-02 21:00; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-02 20:46; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:38; UTC

Uždarbis

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2026-06-02 20:21; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:12; UTC

Uždarbis

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Product Rev $594M

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Adj EPS 85c >PANW

2026-06-02 20:05; UTC

Uždarbis

Palo Alto Networks 3Q Loss $177M >PANW

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

89.58% į viršų

12 mėnesių prognozė

Vidutinis 32.4 USD 89.58%

Aukščiausias 44 USD

Žemiausias 21.6 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Zai Lab Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

91 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.